【In Press】Cinical efficacy of combined topical 0.05% cyclosporin A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction

AIM: To investigate the efficacy of combined topical 0.05% cyclosporin A (CsA, Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction. METHODS: In this retrospective analysis, 53 patients (106 eyes) with meibomian gland dysfunction (MGD) were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% cyclosporine A and preservative free sodium hyaluronate vehicle (CsA group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and at 1, 2, and 3mo for subjective symptoms and objective signs including tear break-up time, schirmer test, corneal staining score, lid margin telangiectasia, meibomian gland secretion, and conjunctival injection. RESULTS: In the short-term treatment, CsA group showed a statistically significant improvement in the ocular surface disease index (P<0.001), tear film break-up time (P=0.004), schirmer test score (P=0.008) and lid margin telangiectasia (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in ocular surface disease index (P<0.001), tear film breakup time (P=0.001), schirmer test score (P=0.029), corneal staining score (P=0.047), eyelid margin telangiectasia (P=0.002), conjunctival injection (P=0.030) were improved better in CsA group than in the control group at 3mo. However, there was no significant difference between the two groups in meibomian gland secretion (P=0.67). CONCLUSIONS: In dry eyes with meibomian gland dysfunction, 0.05% cyclosporin A improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.     

In vivo confocal microscopy in blepharitis

BACKGROUND: Dysfunction of the meibomian glands with inflammation and obstruction has been suggested to be an important factor in the pathogenesis of chronic blepharitis. Few objective tests are, however, available to examine the meibomian glands directly. PATIENTS AND METHODS: Nineteen patients with anterior blepharitis, meibomitis, meibomian gland dysfunction or severe keratoconjunctivitis sicca associated with blepharitis as well as 10 patients with normal lid margins were examined with the HRTII/RCM in vivo confocal microscope. Scans of the tear film, the tarsal conjunctiva, the hair follicles and the meibomian glands were analysed by a masked observer. RESULTS: Patients with normal lid margins exhibited a minimal round cell infiltrate in the tarsal conjunctival epithelium and largely normal ducts of the meibomian glands lined with a multilayered epithelium as well as normal gland acini. In patients with anterior blepharitis, blepharitis associated with autoimmune peripheral ulcerative keratitis and blepharitis in the context of severe dry eye, confocal microscopy disclosed normal meibomian glands. In 12 patients with blepharitis/meibomitis or meibomian gland dysfunction, profound pathology was visible with dilatation and obstruction of the meibomian gland ducts. In 15 of 19 patients with blepharitis/meibomitis, but not in meibomian gland dysfunction, an intense inflammation was observed in the tarsal conjunctival epithelium and stroma. In one patient, demodex folliculorum was evident in vivo. In patients with normal lid margins as well as in patients with blepharitis, hair follicles appeared within normal limits. CONCLUSIONS: In vivo confocal microscopy allowed the examination of the tear film, the tarsal conjunctiva, the lid margin including the lash follicles and the meibomian glands. In patients with meibomian gland disease pathological changes could be visualised and documented objectively. The presence of an inflammatory infiltrate permitted us to differentiate between meibomitis and meibomian gland dysfunction. Changes of the lash follicles do not seem to play an important role in blepharitis. Thus, in vivo confocal microscopy represents an objective technique in the classification and follow-up of patients with blepharitis.     

睑板腺功能障碍患者白内障术后眼表状况

目的：分析睑板腺功能障碍患者白内障手术后眼表状况的改变。方法：前瞻性研究。收集2015年1月至2017年1月期间就诊于上海市浦东医院眼科并接受白内障超声乳化摘除术联合人工晶状体植入术的睑板腺功能障碍患者67例（83眼）,评价术前及术后1、2、3个月的眼表症状指数评分（OSDI）、裂隙灯显微镜下睑缘形态评分、角膜荧光素染色评分（CFS）、泪膜破裂时间（BUT）、基础泪液分泌试验（SⅠT）以及光学相关断层扫描技术计算下泪河高度（TMH）、下泪河深度（TMD）和下泪河面积（TMA）。采用重复测量的方差分析进行统计学处理。结果：术后1、2、3个月的OSDI较术前显著恶化（F=1193.031,P<0.001）,BUT显著下降（F=21.042,P<0.001）;而睑缘形态评分、CFS、TMH、TMD、TMA和SⅠT在术后没有显著改变。结论：睑板腺功能障碍患者白内障术后在不伴有明显器质性改变的情况下就可能出现眼表症状的进一步加重。     

Age-related morphological changes in lid margin and meibomian gland anatomy.

Meibomian gland dysfunction (MGD) is responsible for recurrent irritative symptoms. Attempts to characterize MGD have largely concentrated on microbial and lipid abnormalities in meibomian gland secretions. Few reports describe histological abnormalities in this disease, and fewer still morphological changes. This article follows a previous study that established a classification for MGD. This was based on morphological changes in the meibomian gland and lid margin. Using this classification, we studied the age-related changes in 80 subjects, between 5 and 87 years of age without ocular disease. The lid margin became thicker after childhood. Lid margin vascularity and cutaneous hyperkeratinization increased with age in both lids, whereas, telangiectasia increased with age in the lower lid and squamous blepharitis and posterior lid margin rounding were more common after 50 years of age in the upper lid. Multiple rows of meibomian gland orifices occurred more frequently in the upper than lower lid, and orifice narrowing and pouting increased with age. No age-related changes in the shape or form of the mucocutaneous function, gland ducts, or acini were found. Meibomian gland secretions were less easily expressed in the elderly. We have attempted to define a normal range of lid morphology in healthy children and adults that we believe to be important for the subsequent definition of lid disease, and in particular, posterior blepharitis.     

Association between meibomian gland changes and aging, sex, or tear function

PURPOSE: To study changes in the lid margin and meibomian glands and their association with aging, sex, and tear function. METHODS: We examined 354 eyes in 177 subjects (76 men and 101 women; 21-93 years; mean age, 63.0 +/- 14.3 years) with no ocular symptoms or ocular surface disorders. Anatomic changes in the lid margin were studied using slit-lamp biomicroscopy. Meibomian gland function and morphology were evaluated on the basis of meibum expression and meibography, respectively. Tear function and ocular surface epithelium were assessed with the Schirmer test, by tear film break-up time, and with a fluorescein staining test. RESULTS: Eyes with abnormal lid margin anatomy, hyposecretion of meibum, and meibomian gland dropout were seen in 26 (7.3%), 46 (12.4%), and 68 eyes (18.6%), respectively, with a significant association between each finding and aging (P = <0.0001, 0.0498, and <0.0001, respectively). In patients < or =69 years of age, no significant association was found between meibomian gland-related findings and sex. However, a high incidence of abnormal lid margin and gland dropout was noted in men > or =70 years of age compared with women. No significant association was found between changes in the lid margin and meibomian glands and tear function in patients > or =40 years of age. CONCLUSION: Among symptom-free subjects, we found that changes in the lid margin and meibomian glands were closely related to aging. Among elderly subjects, changes in the anatomic lid margin and meibomian gland morphology were observed more frequently in men than in women. Tear function showed no association with either changes in the lid margin or function of the meibomian glands.     

抗炎治疗睑板腺功能障碍的临床研究

目的探讨抗炎治疗在睑板腺功能障碍患者中的作用,比较抗炎药物1g·L-1氟米龙滴眼液和双氯芬酸钠滴眼液的抗炎作用。方法将48例(96眼)在我院门诊诊断为睑板腺功能障碍患者,随机分为3组(每组各16例32眼),对照组单纯使用人工泪液+抗生素滴眼液+睑板腺局部物理治疗,激素治疗组和非甾体抗炎药物治疗组则在对照组治疗的基础上分别加用1g·L-1氟米龙滴眼液、双氯芬酸钠滴眼液治疗1个月,分别在治疗前、治疗后1周、1个月进行症状评分、视力、裂隙灯检查(睑缘评分等)、泪膜破裂时间检测、角膜荧光素染色检查、泪液分泌试验检查以及眼压检测;并做对比分析。结果 (1)治疗前采用完全随机设计的单因素方差分析进行两两比较,各组间差异均无统计学意义(均为P>0.05);(2)3组症状评分、泪膜破裂时间、角膜荧光素染色评分、泪液分泌试验、睑缘评分治疗前与治疗后1周、1个月分别行配对t检验,差异均有统计学意义(均为P<0.05),提示3种治疗均有效;(3)治疗后1周及1个月:抗炎药物组(激素治疗组和非甾体抗炎药物治疗组)与对照组相比:症状评分和睑缘评分差异均有统计学意义(均为P<0.05),且以上各项指标均值抗炎药物治疗组优于对照组;激素治疗组与非甾体抗炎药物治疗组相比:症状评分、泪膜破裂时间和睑缘评分差异均有统计学意义(均为P<0.05),且以上各项指标均值前者优于后者。结论抗炎治疗对睑板腺功能障碍有效,皮质类固醇激素可以显著改善睑板腺功能障碍患者的症状和体征,抗炎效果优于非甾体抗炎药物。     

睑缘炎患者睑板腺形态变化及其与干眼的关系

背景 睑缘炎是一种常见的眼表疾病,常累及睑板腺体,而睑板腺体所分泌的脂质是泪膜的重要组成成分之一.泪膜稳定性的破坏可导致干眼相关症状,可以说睑缘炎是干眼发病的因素之一,但二者之间的关系有待进一步研究. 目的 使用非接触式红外线睑板腺观察仪观察睑缘炎患者睑板腺腺体的形态,并与干眼相关检查进行相关性分析. 方法 采用病例观察的设计方法对睑缘炎患者睑板腺形态改变与干眼症的关系进行研究.选取2010年9月至2011年4月于河南省眼科研究所眼科门诊依据PPP标准诊断为睑缘炎的患者83例83眼,取得患者的知情同意后,在裂隙灯下行眼前节检查睑缘畸形评分、泪液分泌( Schirmer Ⅰ)试验、泪膜破裂时间(BUT)、角膜荧光素染色评分及结膜充血评分,采用泪膜干涉仪行泪膜形态分级,采用非接触式红外线睑板腺摄像仪行睑板腺腺体缺失分级,对睑缘炎睑板腺腺体缺失分级与上述检查结果的关系进行评估.结果 不同年龄组不同性别间睑缘炎的频数分布差异无统计学意义(x2=2.69,P=0.75).睑缘炎患者的睑板腺腺体缺失分级与年龄星弱的正相关(r=0.58,P=0.00),但与性别无明显相关性(r=-0.09,P=0.99);患者睑板腺体缺失与睑缘畸形评分及结膜充血评分均呈弱的正相关(r=0.64,P=0.00;r=0.50,P=0.00);与泪膜影像分级及角膜染色评分均呈弱的正相关(r=0.23,P=0.04;r=0.50,P=0.00),与BUT呈弱的负相关(r=-0.32,P=0.00),但与Schirmer Ⅰ试验结果无明显相关性(r=-0.05,P=0.69).不同年龄组男性和女性的睑板腺缺失分级评分差异无统计学意义(Z=-0.09,P=0.93).结论 睑缘炎可引起蒸发过强型干眼,且患者的睑板腺体随年龄的增长缺失程度加重.非接触式红外线睑板腺观察仪作为一种有效、快速、无刺激地观察睑板腺体形态的仪器,可作为一项常规检查来辅助诊断睑缘炎.     

年龄相关性白内障患者睑板腺与眼表状况分析

背景 睑板腺是位于上下睑板内一种特殊分化的皮脂腺,其形态学和功能学的严重改变与多种眼表疾病有关,研究睑板腺形态学和功能变化与干眼的关系具有重要的临床意义. 目的 观察年龄相关性白内障患者的睑板腺形态、结构及功能变化,探讨衰老与睑板腺功能障碍(MGD)及眼表健康状态的关系.方法 采用系列病例观察研究方法,选取2016年3-9月在山西省眼科医院就诊的45岁以上年龄相关性白内障患者93例93眼作为研究对象,按照年龄将患者分为45～ 59岁组和≥60岁组;按照睑板腺缺失范围将受检眼分为睑板腺缺失范围≥1/3组和睑板腺缺失范围＜1/3组.采用裂隙灯显微镜检查眼表组织、睑缘形态、睑板腺开口形态和睑脂性状;采用眼表疾病指数(OSDI)量表问卷对眼表症状进行调查和评分;采用眼表综合分析仪测定受检眼泪膜破裂时间(BUT)、泪河高度、睑板腺缺失、结膜充血及角膜荧光素染色情况.结果 93例受检者均无干眼主观症状,OSDI问卷评分均＜12分.裂隙灯显微镜检查受检眼均未发现睑缘及皮肤黏膜交界线的形态学变化,无睑板腺开口、睑脂排出及睑脂性状的异常.眼表综合分析仪检查发现,42眼BUT缩短,占45.16％;52眼泪河高度下降,占55.91％;58眼睑板腺缺失范围≥1/3,占62.27％.45 ～59岁组受检眼睑板腺缺失评分为1.65±0.79,≥60岁组为1.86±0.72,差异无统计学意义(t=1.301,P=0.197).但相关分析示年龄与睑板腺缺失评分呈弱正相关(r5=0.323,P=0.002),与BUT及泪河高度均无明显相关性(r=0.154,P=0.141;r =-0.024,P=0.821);睑板腺缺失评分与BUT呈负相关(r3=-0.251,P=0.015),睑板腺缺失范围≥1/3组BUT异常的发生眼数明显多于缺失范围＜1/3组,差异有统计学意义(P=0.018). 结论 中老年人随着年龄的增长,睑板腺缺失逐渐加重;睑板腺缺失范围较大者发生泪膜不稳定的风险增加;早期MGD患者体征先于症状出现,临床工作中应重视无症状的MGD患者.     

眼表综合分析仪在儿童早期前睑缘炎临床分析中的应用

目的利用眼表综合分析仪对儿童早期前睑缘炎患者的眼表情况进行观察,分析其临床特点。方法描述性研究。选取2015年7月至2016年5月就诊于山西省眼科医院门诊,经裂隙灯显微镜检查确诊为早期前睑缘炎的儿童患者40例（80眼）,年龄4~14岁。对患儿睑缘炎体征进行评分,利用眼表综合分析仪检查其泪膜破裂时间（BUT）、泪河高度,并进行眼表充血、睑板腺缺失及角膜荧光素钠染色评分,对所得数据进行Spearman秩相关分析。结果80眼中,58眼（72%）BUT缩短;50眼（62%）泪河高度下降;15眼（19%）发生角膜上皮点状缺损;25眼（31%）睑板腺缺失范围＞1/3。睑缘炎体征评分与BUT、泪河高度、角膜荧光染色评分及睑板腺缺失评分不相关;睑板腺缺失评分与BUT呈负相关（r=-0.253,P=0.024）,与角膜荧光染色评分呈正相关（r=0.563,P＜0.001）。结论儿童早期前睑缘炎患者泪膜稳定性下降,同时合并睑板腺缺失的患者易继发干眼。     

热敷按摩改善睑板腺功能障碍患者的白内障术后疗效

目的：评价白内障术前进行眼睑热敷联合睑板腺按摩对白内障合并轻中度睑板腺功能障碍（MGD） 患者白内障术后临床效果的改善。方法：前瞻性临床研究。收集2019年9月至2020年6月于温州医科大学附属眼视光医院杭州院区就诊的50～85岁轻中度MGD合并白内障的患者,按随机数字表法分为实验组和对照组,实验组先接受3次眼睑热敷联合睑板腺按摩治疗再行白内障手术,对照组直接行白内障手术。分别记录MGD治疗前、治疗后以及白内障术后1周、1个月、3个月时的泪液分泌试验（SⅠT）、泪膜破裂时间（TBUT）、角结膜染色评分、睑板腺功能评分;眼表综合分析仪（keratograph 5M）检查并记录非侵入性泪河高度（NITMH）、非侵入性泪膜破裂时间（NITBUT）和睑板腺缺失范围（MGL）;采用眼表疾病指数（OSDI）问卷得分进行评估。使用广义估算方程（GEE）、广义线性混合模型（GLMM）、独立样本t检验及Mann-Whitney U检验进行数据分析。结果：共纳入77例（77眼）, 最终纳入分析68例（68眼）,每组34例。实验组在MGD治疗后,睑缘形态、睑板腺排出能力、SⅠT、 TBUT及OSDI评分较MGD治疗前明显好转（P<0.05）;角膜点染在白内障术后1周时较治疗前增加 （P=0.002）,至术后1个月时恢复至治疗前水平。组间比较发现,实验组睑脂质量变化量在白内障术后各时间点均明显优于对照组（P<0.05）;白内障术后1周时,实验组睑缘形态的变化量小于对照组, 术后1个月时,NITMH变化量小于对照组,而OSDI评分变化量大于对照组（P<0.05）,实验组症状及体征更轻;对照组在白内障术后1周时,睑缘形态及SⅠT明显变差,至术后1个月时恢复至术前水平; 睑脂质量在术后1周时变差,NITMH在术后1个月时减少,二者至术后3个月时恢复至术前水平。结论： 白内障术前采用眼睑热敷联合睑板腺按摩治疗MGD,可改善术后睑板腺功能状态,缓解干眼症状。     

Tear film lipid layer thickness measurement from Ocular Surface Analyzer as a marker to monitor treatment of meibomian gland dysfunction in a study comparing physiological detergent-free eyelid wipes with conventional therapy: A randomized trial

Purpose:To compare the efficacy of physiological, non-detergent eyelid wipes with conventional lid hygiene in patients with meibomian gland dysfunction (MGD).Methods:Fifty participants with MGD were recruited and randomized into two groups. Participants in group I used Evolve Pure™ Eyewipes twice a day to clean the eyelid debris along with standard therapy (antibiotic and lubricants) and participants in group II followed lid hygiene with warm compresses along with standard therapy. Symptoms, ocular surface assessment (lipid layer thickness, tear meniscus height, non-invasive tear film breakup time, and meibography), slit-lamp biomicroscopy (eyelash contamination, meibomian gland blockage, meibomian gland secretion, and meibomian gland telangiectasia) and tear film osmolarity were noted at baseline and 90 days after therapy.Results:Significant improvement in symptoms and signs of MGD was observed in both groups after treatment (P < 0.001); however, the clinical improvement was better with the use of eyelid wipes. Lipid layer thickness increased significantly in group I (P = 0.0006) and group II (P = 0.0002), which was maintained even after adjusting for sociodemographic variables such as age, sex, and severity score of symptoms and signs.Conclusion:Lipid layer thickness of the tear film is a sensitive marker in monitoring response to treatment in patients with MGD. The use of physiological detergent-free eyelid wipes is non-inferior to lid hygiene and warm compresses, which remains the mainstay for treatment of MGD; the clinical improvement with eyelid wipes was noted to be better.     

Trockenes Auge bei Kontaktlinsenträgern

Contact lens-associated dry eye symptoms have mostly been therapeutically addressed using artificial tears containing hyaluronic acid to supplement tear film volume with often unsatisfactory results. However, the main reason for contact lens-associated dry eye is not the lack of tear fluid but the lack of tear film stability due to meibomian gland dysfunction leading to reduction of the lipid film of tears. This is associated with increased evaporation of the aqueous phase of tear fluid and a measurable hyperosmolarity of the residual “denatured” tear film. A subsequent inflammatory reaction of the ocular surface then leads to the vicious circle of dry eye. The aim of this review is to summarize current study results on this topic and to give practical advice on how to address dry eye symptoms in contact lens wearers more accurately. For most contact lens-associated dry eye symptoms a combined therapy with unpreserved artificial tears plus phospholipid-liposome eye spray yields the best results. In cases of additional signs of blepharitis the regular use of phospholipid-liposome solution for lid margin hygiene is beneficial.     

Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction

AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67). CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.     

Evaluation of an Automated Thermodynamic Treatment (LipiFlow®) System for Meibomian Gland Dysfunction: A Prospective,Randomized, Observer-Masked Trial

PurposeTo compare the effectiveness of a single LipiFlow^® treatment with combined lid warming and massage in patients with meibomian gland dysfunction (MGD).MethodsIn this prospective, randomized, crossover, observer-masked clinical trial, subjects were randomized to receive either a single 12-min LipiFlow-LipiFlow Thermal Pulsation (LTP) system treatment or to perform combined twice-daily lid warming and massage for 3 months. All subjects were examined before, and 1 and 3 months after initiation of treatments. Investigated parameters included subjective symptoms, lipid layer thickness, meibomian gland assessment, tear break-up time, tear osmolarity, corneal and conjunctival staining, Schirmer test values, and tear meniscus height.ResultsA total of 31 subjects completed the 3-month follow-up. At 1 and 3 months, patients in the LipiFlow treatment group had a significant reduction in Ocular Surface Disease Index (OSDI) scores compared with those in the lid-margin hygiene group. Both treatments produced a significant improvement in expressible meibomian glands compared to the baseline parameters, but no significant difference was noted between the two groups. The other investigated objective parameters did not show a significant difference.ConclusionResults of our study show that a single LipiFlow treatment is as least as effective as a 3-month, twice-daily lid margin hygiene regimen for MGD. However, the present study was observer-masked only, and therefore a placebo effect may have confounded any improvements in subjective symptoms and other parameters in both groups.     

Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis

Background: Posterior blepharitis is an eyelid disease primarily of the meibomian glands. Bacteria and chronic inflammation are contributing factors for meibomian gland disease, which leads to ocular surface and tear film alterations and chronic patient symptoms. Azithromycin 1.0% ophthalmic solution is a broad spectrum topical antibiotic with anti‐inflammatory properties. The present study evaluates the efficacy of azithromycin 1.0% ophthalmic solution in the treatment of the clinical signs and symptoms, including vision‐related function, associated with meibomian gland dysfunction. Methods: In an open label study, 33 patients with meibomian gland dysfunction were treated with azithromycin 1.0% ophthalmic solution twice a day for two days, then every evening for a total of 30 days. Tear break‐up time, corneal staining, conjunctival staining, Schirmer scores with anaesthetic, meibomian gland score and patient's symptom scores were evaluated at baseline and after 30 days of treatment. The Ocular Surface Disease Index (OSDI) was administered at baseline, after two weeks of treatment and after 30 days of treatment. Results: Twenty‐six of 33 patients completed the study. Tear break‐up time and Schirmer score increased by 52.7 per cent (p < 0.0001) and 24 per cent (p < 0.05), respectively. There was a reduction in corneal and conjunctival staining by 83.2 and 67.9 per cent, respectively (p < 0.0001). Lid margin scores were reduced by 33.9 per cent (p < 0.0001). The patient's symptom score improved from 2.73 at baseline to 2.21 after 30 days of treatment (p < 0.01). The mean OSDI at baseline was 34.44. After two weeks and 30 days of treatment, the ODSI was 14.51 and 13.15 respectively (p < 0.0001). Conclusion: These results demonstrate clinically and statistically significant improvement in the signs and symptoms associated with posterior blepharitis. Based on these results, azithromycin 1% ophthalmic solution offers a viable option for the treatment of posterior blepharitis.     

提高对睑板腺功能障碍的认识 重视睑板腺功能障碍相关性干眼的药物治疗

睑板腺功能障碍（MGD）是临床常见的眼表疾病,以睑板腺终末导管的阻塞和／或睑板腺分泌物质或量的改变为特征,导致脂质向泪膜的排出减少,引起泪液蒸发过强。睑缘和睑板腺的炎症是引起睑板腺阻塞,进而导致MGD的直接原因,可引起眼表功能的异常。MGD的诊断主要依靠临床症状与体征,其症状与干眼的症状相似,因此无诊断特异性。体征主要包括睑缘形态的变化、睑板腺分泌异常和睑板腺缺失。MGD的治疗方法包括热敷、清洁睑缘、促进睑板腺的分泌、抗菌、抗炎治疗及润滑眼表,中度、重度MGD患者可给予必要的抗炎治疗,常用的抗炎药物有糖皮质激素、非甾体类抗炎药及免疫抑制剂。临床医师在进行眼部疾病的检查时应重视睑板腺的功能状态,尤其在角膜屈光手术及内眼手术前更应重视MGD的筛查,以免术后引起严重的眼表并发症,有效规避医疗风险。     

眼睑加热装置联合眼睑按摩对办公室干眼疗效观察

目的:比较眼睑加热联合眼睑按摩与人工泪液对办公室干眼的疗效.方法:本研究纳入办公室工作人员干眼患者60例60眼,并随机分为2组.对照组给予人工泪液治疗,试验组给予蒸汽润眼仪联合眼睑按摩治疗.所有受检者均在治疗前、治疗后2、4wk按照以下顺序进行检查:眼表疾病指数问卷表、泪膜破裂时间、角膜荧光素染色、Schirmer I试验与睑板腺分泌功能评估.结果:入选60例60眼干眼患者中,48例48眼患者(对照组23例23眼,试验组25例25眼)患有睑板腺功能障碍.4wk的治疗过程中,眼表疾病指数评分(F分组=41.63,P<0.01)、泪膜破裂时间(F分组=60.47,P<0.01)与睑板腺分泌物性质评分(F分组=12.12,P<0.01),实验组疗效均优于对照组.角膜荧光素染色(F分组=1.79,P>0.05)、泪液分泌量(F分组=0.17,P>0.05)与睑板腺管通畅率评分(F分组=0.68,P>0.05),两组间差异无统计学意义.结论:睑板腺功能障碍是我国办公室干眼的重要病因,眼睑加热联合眼睑按摩对办公室工作人员干眼疗效优于人工泪液.     

Meibomian gland dysfunction in chronic blepharitis

We examined 57 patients with symptoms of chronic blepharitis using meibomian gland expression, meibography, tear osmolarity, and the Schirmer's test. We also performed meibography on 20 normal patients free of chronic blepharitis. We found that 42 blepharitis patients (74%) had evidence of meibomian gland loss, whereas only four of 20 normal patients (20%) had any gland dropout. We performed cluster analysis on the data from the patients with blepharitis and found that these patients tended to fall into distinct groups with clinically relevant characteristics. We also found that tear osmolarity correlated positively with gland dropout (+0.413) and negatively with excreta volume (-0.499). This study demonstrates that an objective analysis of meibomian gland function may be used to assess chronic blepharitis and define subsets of blepharitis with measurable differences. It also supports the significance of meibomian gland dysfunction on tear osmolarity and the evaporative state of the eye.     

Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?

PURPOSE: This study's purpose was to determine whether complete androgen insensitivity syndrome (CAIS) is associated with alterations in the meibomian gland and ocular surface. METHODS: Individuals with CAIS, as well as age-matched female and male controls, completed questionnaires which assessed dry eye symptoms and underwent slit lamp evaluations of the tear film, tear meniscus, lids and lid margins and conjunctiva. The quality of meibomian gland secretions was also analyzed. RESULTS: Our results demonstrate that CAIS is associated with meibomian gland alterations and a significant increase in dry eye signs and symptoms. Clinical assessment revealed that CAIS women, as compared to controls, had a significant increase in telangiectasia, keratinization, lid erythema and orifice metaplasia of the meibomian glands, and a significant decrease in the tear meniscus and quality of meibomian gland secretions. Questionnaire results showed that dry eye symptoms were increased over twofold in CAIS individuals, as compared to controls, including a significant increase in the sensations of dryness, pain and light sensitivity. CONCLUSION: Our results suggest that androgen insensitivity may promote meibomian gland dysfunction and an increase in the signs and symptoms of dry eye.     

Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction

Purpose

To evaluate the efficacy and safety of intense pulsed light (IPL) combined with meibomian gland expression (MGX) for treatment of refractory meibomian gland dysfunction (MGD).